Comment on "nRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis"

Science Translational Medicine

Volumn 8, Issue 349, 2016, Pages

  Decalf, Jérémie ^a   Da Silva, Rosa Barreira ^a   Werneke, Scott ^a   Albert, Matthew L ^a,b,c  

^a GENENTECH INC   (United States)

^b INSTITUT PASTEUR   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIOXIDANT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SAXAGLIPTIN; SITAGLIPTIN; TRANSCRIPTION FACTOR NRF2;

B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RISK; CELL MIGRATION; CELLS BY BODY ANATOMY; DISEASE ACTIVITY; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; HEMATOPOIETIC CELL; HUMAN; IMMUNOCOMPROMISED PATIENT; LETTER; METASTASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR IMMUNITY; NEOPLASM; OXIDATIVE STRESS;

ANTIOXIDANTS; HUMANS; HYPOGLYCEMIC AGENTS; NEOPLASMS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS;

EID: 84980041509     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf9121     Document Type: Letter

References (0)